Tejara Capital Ltd Makes New $381,000 Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

Tejara Capital Ltd acquired a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 51,967 shares of the company's stock, valued at approximately $381,000.

Other institutional investors and hedge funds have also modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in shares of Vir Biotechnology in the 4th quarter valued at about $60,000. PNC Financial Services Group Inc. raised its holdings in Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock worth $61,000 after purchasing an additional 1,999 shares during the period. KBC Group NV raised its holdings in Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after purchasing an additional 5,177 shares during the period. CIBC Asset Management Inc acquired a new position in Vir Biotechnology in the 4th quarter worth about $74,000. Finally, Captrust Financial Advisors acquired a new position in Vir Biotechnology in the 3rd quarter worth about $118,000. Institutional investors and hedge funds own 65.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Barclays upped their price target on Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 price target on shares of Vir Biotechnology in a report on Thursday, February 27th. Morgan Stanley raised Vir Biotechnology from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. JPMorgan Chase & Co. increased their target price on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a report on Thursday, January 9th. Finally, HC Wainwright reissued a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $35.67.

Remove Ads

Insider Activity

In related news, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the completion of the transaction, the executive vice president now directly owns 79,460 shares in the company, valued at approximately $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the transaction, the director now owns 1,312,391 shares of the company's stock, valued at $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,859 shares of company stock worth $326,458 over the last ninety days. Corporate insiders own 15.60% of the company's stock.

Vir Biotechnology Stock Up 0.9 %

Shares of Vir Biotechnology stock traded up $0.06 during mid-day trading on Friday, reaching $6.93. 2,903,576 shares of the stock traded hands, compared to its average volume of 1,276,960. The business has a 50-day moving average of $9.15 and a 200 day moving average of $8.38. The stock has a market capitalization of $950.40 million, a PE ratio of -1.77 and a beta of 1.17. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09. The business had revenue of $12.37 million during the quarter, compared to analyst estimates of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. On average, equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).